Hematology-OncologyAMLBệnh Bạch Cầu Tế Bào Phôi
Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib
By MedXY|Mar 29, 2026
A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for